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in patients with hepatitis B virus (HBV) is associated with rapid
progression to liver cirrhosis and hepatocellular carcinoma.
Treatment options are limited, and no vaccine is available.
Although HDV-specific CD8þ T cells are thought to control thevirus, little is known about which HDV epitopes are targeted by
virus-specific CD8þ T cells or why these cells ultimately fail to
control the infection. We aimed to define how HDV escapes the
CD8þ T-cell–mediated response. METHODS: We collected
plasma and DNA samples from 104 patients with chronic HDV
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
HDV infection is associated with severe liver disease, but
little is known about the corresponding virus-specific
CD8þ T cells, which are thought to mediate immune
protection against HDV.
NEW FINDINGS
In persistent infection, HDV mutates to escape from the
virus-specific CD8þ T cell response. At the population-
level, HDV has evolved to evade from recognition in the
context of common HLA class I alleles.
LIMITATIONS
The observational nature of this study precludes formal
identification of a causal association between viral
escape and CD8þ T-cell failure in the context of
infection with HDV.
IMPACT
These results suggest that viral escape should be
considered as a key parameter in the design of immune-
based interventions to prevent and treat liver disease
associated with HDV.
May 2019 Viral Escape From HDV-Specific CD8+ T Cells 1821and HBV infection at medical centers in Europe and the Middle
East, sequenced HDV, typed human leukocyte antigen (HLA)
class I alleles from patients, and searched for polymorphisms in
HDV RNA associated with specific HLA class I alleles. We pre-
dicted epitopes in HDV that would be recognized by CD8þ T
cells and corresponded with the identified virus poly-
morphisms in patients with resolved (n ¼ 12) or chronic (n ¼
13) HDV infection. RESULTS: We identified 21 polymorphisms
in HDV that were significantly associated with specific HLA class
I alleles (P < .005). Five of these polymorphisms were found to
correspond to epitopes in HDV that are recognized by CD8þ T
cells; we confirmed that CD8þ T cells in culture targeted these
HDV epitopes. HDV variant peptides were only partially cross-
recognized by CD8þ T cells isolated from patients, indicating
that the virus had escaped detection by these cells. These newly
identified HDV epitopes were restricted by relatively infrequent
HLA class I alleles, and they bound most frequently to HLA-B. In
contrast, frequent HLA class I alleles were not associated with
HDV sequence polymorphisms. CONCLUSIONS: We analyzed
sequences of HDV RNA and HLA class I alleles that present
epitope peptides to CD8þ T cells in patients with persistent HDV
infection. We identified polymorphisms in the HDV proteome
that associate with HLA class I alleles. Some variant peptides in
epitopes from HDV were only partially recognized by CD8þ T
cells isolated from patients; these could be mutations that allow
HDV to escape the immune response, resulting in persistent
infection. HDV escape from the immune responsewas associated
with uncommon HLA class I alleles, indicating that HDV evolves,
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SLH10% of hepatitis B virus (HBV)–seropositive
individuals, affecting 15–20 million people worldwide.1
Patients with simultaneous HDV/HBV infection often expe-
rience severe acute hepatitis, with an enhanced risk of
fulminant disease, but frequently clear both viruses. In
contrast, HBV-seropositive patients who become super-
infected with HDV generally develop chronic HDV/HBV
infection. These patients have a high risk of rapid progres-
sion to liver cirrhosis and hepatocellular carcinoma. At
present, the sole treatment option for chronic HDV/HBV
infection is pegylated interferon (IFN) alfa, which is usually
administered for 48 weeks. However, only approximately
30% of patients respond to treatment, and many subse-
quently develop viral relapse.2
Virus-specific CD8þ T cells are thought to play a key role
in the outcome of HDV/HBV infection. This contention has
been supported by vaccination studies in mice and wood-
chucks.3 However, little is known about naturally occurring
HDV-specific CD8þ T-cell responses, despite the urgent
need for novel prophylactic and therapeutic interventions.
The HDV genome encodes a single viral protein, hepatitis
delta antigen (HDAg), translated as large and small variants
(L-HDAg and S-HDAg, respectively). The only differencebetween these 2 proteins is a 19–amino acid extension at the
C-terminus of L-HDAg. An initial report described 2 HDV-
specific CD8þ T-cell epitopes in human leukocyte antigen
(HLA)-A*02 transgenic mice and patients with resolved HDV
infection, but these findings were not confirmed in patients
with persistent HDV infection.4 A subsequent report sug-
gested that immune exhaustion may impair the efficacy of
HDV-specific CD8þ T cells in vivo.5 In a recent study, we
identified 2 HLA-B*27–restricted HDV-specific CD8þ T-cell
epitopes, both of which were subject to viral escape by mu-
tation.6 Of note, HLA-B*27 is associated with spontaneous
clearance of hepatitis C virus (HCV) and elite control of hu-
man immunodeficiency virus (HIV), and HLA-B*27–
restricted CD8þ T-cell responses drive viral evolution in
patients infected with HCV or HIV.7 It nonetheless remains
unclear if viral escape is a generalizable phenomenon that
underlies immune failure in patients infected with HDV.
In the present study, we analyzed HLA class I–associated
viral sequence polymorphisms across the entire HDV
genome as surrogate markers of CD8þ T-cell–driven viral




LIVERescape. These “HLA footprints” were used to identify CD8þ
T-cell epitopes, confirm predicted escape mutations, and
explore features of the host–virus interactome, providing
mechanistic insights into adaptive immunity against HDV.Materials and Methods
Patients and Samples
Patients with chronic HDV/HBV infection (n ¼ 104) were
recruited from 8 medical centers located in Germany (Bonn,
Düsseldorf, Essen, Hannover, and Munich), Spain, Italy, and Iran.6
Viral sequences and HLA class I genotypes were determined
according to standard protocols.6 CD8þ T-cell assays were per-
formed with additional samples obtained from 12 patients with
resolved HDV infection and 13 patients with chronic HDV/HBV
infection, recruited from Freiburg, Hamburg, and Munich (Ger-
many). All patients were infected with HDV genotype 1. Patient
characteristics are summarized in Supplementary Tables 1 and 2.
Ethical approval was granted by the Ethik-Kommission der
Albert-Ludwigs-Universität Freiburg (no. 369/15). Written
informed consent was obtained in all cases according to federal
guidelines and the Declaration of Helsinki. Venous blood samples
(50 mL per draw) were collected in EDTA-anticoagulated tubes.
Peripheral blood mononuclear cells (PBMCs) were isolated
with lymphocyte separation medium density gradients (Pancoll
separation medium, PAN Biotech GmbH; Aidenbach, Germany)
and resuspended in RPMI 1640 medium supplemented with
10% fetal calf serum, 1% penicillin/streptomycin, and 1.5%
HEPES buffer 1 mol/L (complete medium; all additives from
Thermo Scientific (Waltham, MA).Table 1.HLA Class I–Associated Viral Sequence Polymorphism
No. HLA AA position Mutation P value e
1 B*15 170 S170N 2.9 3 10–8 S
2 B*13 33 D33E .0001 D
3 B*37 101 D101E .0002 Q
4 A*29 63 K63R .0002 —
5 A*30 47 D47E .0010 K
6 B*37 89 P89T/I .0011 V
7 B*49 37 V37A/T .0015 E
8 B*13 100 Q100K .0018 R
9 B*51 81 V81I .0019 —
10 B*13 43 K43R .0021 D
11 B*41 158 G158A/D/M .0023 —
12 B*18 47 E47D .0027 D
13 A*33 37 V37T/A .0028 E
14 B*14 107 A107T .0028 D
15 A*30 49 P49L/S .0031 K
16 B*41 139 R139K .0034 R
17 B*13 96 D96E .0035 R
18 B*27 105 R105K .0039 R
R
19 B*38 131 K131G .0039 —
20 B*13 113 K113R .0043 R
K
21 A*68 134 T134A .0045 L
NOTE. Confirmed epitopes are displayed in bold.
AA, amino acid; ND, not done.Peptides, Antibodies, and Tetramers
Peptides were synthesized with a free amine NH2 terminus
and a free acid COOH terminus with standard Fmoc chemistry
(Genaxxon Bioscience, Ulm, Germany). Anti-CD8 (RPA-T8, 1:100;
SK1, 1:300), anti-CD38 (Hb7, 1:200), anti-CD45RA (HI100, 1:50),
anti-IFN-g (4S.B3, 1:50), and anti–programmed cell death protein
1 (PD-1) (EH12.1, 1:33) were purchased from BD Biosciences
(Germany). Anti-Bcl-2 (Bcl-2/100, 1:200), anti-CCR7 (G043H7,
1:33), anti-CD8 (RPA-T8, 1:400), and anti-CD127 (A019D5, 1:33)
were purchased from BioLegend (San Diego, CA). Anti-CD14
(61D3, 1:100), anti-CD19 (HIB19, 1:100), anti-Eomes (WD1928,
1:50), anti-killer cell lectin-like receptor G1 (KLRG1) (13F12F2,
1:33), and anti-T-bet (4B10, 1:200) were purchased from Thermo
Scientific. Anti-T-cell factor (1TCF1) (C63D9, 1:100) was pur-
chased from Cell Signaling Technology (Danvers, MA). Tetrameric
complexes of HLA-B*15:01/L-HDAg170–179 SMQGVPESPF were
generated as described previously.8
Analysis of HDV Sequences and HLA Class
I-Associated Viral Polymorphisms
Total RNA was extracted from serum samples and reverse
transcribed into cDNA with Moloney Murine Leukemia
Virus Reverse Transcriptase (Promega, Madison, WI) and the
HDV-specific primer 771R (50-CGGTCCCCTCGGAATGTTG-30).
The L-HDAg-encoding region was amplified from cDNA
with Pfu DNA Polymerase (Promega) in a 2-step nested poly-
merase chain reaction (PCR) incorporating the HDV-specific
primers 891-F (50-AGGTCGGACCGCGAGGAGGT-30), 339-R
(50-GCTGAAGGGGTCCTCTGGAGGTG-30), 912-F (50-GAGATGC
CATGCCGACCCGAAGAG-30), and 1674-R (50-AGAAAAGAGTAAs and HDV-Specific CD8þ T Cell Epitopes
AA sequence
pitope candidate AA range
Positive responses/
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Figure 1. HLA-B*15–restricted CD8þ T-cell responses specific for L-HDAg170–179 drive viral escape. (A) P values for the as-
sociations between HDV sequence polymorphisms and the presence of HLA-B*15, plotted for each amino acid residue in the
L-HDAg protein. The cutoff for significance was set at P ¼ .005 (dotted red line). (B) Predicted HLA-B*15 binding affinity of
candidate peptide epitopes in L-HDAg. IC50 values were predicted for 8mers, 9mers, and 10mers with the ANN 3.4 method
(www.iedb.org). The best hit corresponding to the confirmed HLA-B*15–restricted epitope L-HDAg170–179 is highlighted in
green. (C) Viral sequences from individual HLA-B*15þ and HLA-B*15– patients compared with the consensus sequence
derived from all 104 patients (all HLA-B*15þ patients are shown above the line, and the first 20 HLA-B*15– patients are shown
below the line). Dots indicate agreement with consensus, and single-letter amino acid codes indicate variation from
consensus. The HLA-B*15–associated polymorphism S170N is highlighted in dark grey, and the confirmed HLA-B*15–
restricted epitope L-HDAg170–179 is highlighted in grey. (D) PBMCs from HLA-B*15
þ patient 13 (2 years after IFN treatment)
were expanded in the presence of the wild-type or variant peptide corresponding to the L-HDAg170–179 epitope. After 14 days,
cells were restimulated in parallel with each peptide and tested for IFN gamma production. Negative controls without peptide
restimulation and positive controls stimulated with phorbol myristate acetate/ionomycin are also shown. (E) Equivalent results
after restimulation with each peptide in serial dilution assays. PBMCs from patient 13 (2 and 7 years after IFN treatment) and
HLA-B*15þ patient 21 were processed and tested as in D. M, mol/L; P, patient; PMA, phorbol myristate acetate.
















GAGYACTGAGG-30). The following thermal profile was used for
all PCRs: (i) 94C for 10 minutes; (ii) 94C for 30 seconds, 54C
for 45 seconds, and 72C for 90 seconds (35 cycles); and (iii)
72C for 7 minutes. PCR products were purified with a QIA-
quick Gel Extraction Kit (Qiagen, Hilden, Germany) and
sequenced on an ABI 3730xl DNA Analyzer (Eurofins Genomics
Germany GmbH; Ebersberg, Germany) with the internal
primers 912-F and 1674-R. All sequences were submitted to
GenBank (accession nos. MF175257–MF175360). HDV se-
quences were aligned with ClustalX2 software.9 HLA class I
associations with amino acid residues at each alignment posi-
tion were tested using the R package SeqFeatR (https://
seqfeatr.zmb.uni-due.de).10 The Fisher exact test was used todetermine significant associations in a 2  2 contingency table
format with counts for observed combinations of amino acids
and HLA class I allotypes at each alignment position. Further
analyses were based on a cutoff P value of <.005.Prediction of HDV-Specific CD8þ T-Cell Epitopes
Viral amino acid sequences, 15 residues N-terminal and 15
residues C-terminal, of the identified HLA class I–associated
viral sequence polymorphisms were analyzed for the corre-
sponding binding motifs with 4 online prediction tools: ANN 3.4
and netMHCpan 2.8 on the Immune Epitope Database
website,11,12 SYFPEITHI,13 and BIMAS.14 The 8mer, 9mer, and
Figure 2. Viral sequence polymorphisms are associated with infrequent HLA class I alleles and spare the N- and C-termini of L-
HDAg. (A) Distribution of identified HLA footprints across L-HDAg. Red arrows indicate HLA footprints corresponding to
confirmed (predescribed or newly identified) epitopes. Filled black arrows indicate HLA footprints corresponding to predicted
epitopes. Empty black arrows indicate HLA footprints without defined or predicted epitopes. Newly identified epitopes are
shown as red bars, and pre-described epitopes are shown as blue bars. (B) HLA-A and HLA-B allele frequencies in the study
cohort compared with reference populations from Germany, Italy, and Iran. HLA class I alleles identified in at least 2 patients in
the study cohort are shown (HLA class I alleles present in 1 patient cannot reach statistical power for the identification of HLA
class I–associated viral sequence polymorphisms). Footprint-linked HLA class I alleles are shown in bold and marked with an
arrowhead.




LIVER10mer peptides were tested if available via the respective
prediction tool. A half maximal inhibitory concentration (IC50)
of 1000 nmol/L, a SYFPEITHI score of 20, and a BIMAS
score of 20 were used as cutoffs. Candidate epitopes were
ranked against epitopes predicted across the entire sequence of
L-HDAg.Peptide-Specific CD8þ T-Cell Lines
PBMCs were activated with peptides, as described previ-
ously.15 Briefly, 4  106 PBMCs were stimulated once with 10
mg/mL peptide and 0.5 mg/mL anti-CD28 (BD Biosciences) and
fed every 3 days with complete medium containing 20 U/mL
recombinant interleukin (IL)-2 (Miltenyi Biotec, Bergisch
Gladbach, Germany). Peptide-specific CD8þ T-cell lines were
used for experimental purposes after 14 days.Intracellular IFN Gamma Staining
Procedures were carried out as described previously.16
Briefly, expanded CD8þ T cells or peptide-specific CD8þ T-cell
lines (0.2  106 cells per well in a 96-well plate) were stim-
ulated with peptides (10 mg/mL) in the presence of 50 U/mL
recombinant IL-2 and 1 mL/mL brefeldin A (BD Biosciences).
After 5 hours, cells were stained with 7-aminoactinomycin Dand anti-CD8, fixed/permeabilized with Cytofix/Cytoperm,
and stained with anti-IFN gamma (all reagents from BD Bio-
sciences). Stained cells were fixed in phosphate-buffered sa-
line (PBS) containing 2% paraformaldehyde. Data were
acquired with an BD FACSCanto II flow cytometer (BD Bio-
sciences) and analyzed with FlowJo software, version 10
(FlowJo, Ashland, OR).
HLA Class I Tetramer-Based Analysis and Cell
Enrichment
Tetramer staining procedures were carried out as described
previously.17 Briefly, 1  106 PBMCs per well were incubated
in a 96-well plate with the relevant HLA class I tetramer for 15
minutes at 37C. Cells were then washed 3 times with PBS
containing 1% fetal calf serum and stained with the indicated
surface and/or intracellular antibodies. Dead cells were
excluded from the analysis with the fixable viability dye
eFluor780 (1:5000, eBioscience, Germany). Cytoplasmic and
nuclear molecules were shown with a FoxP3/Transcription
Factor Staining Buffer Set (eBioscience). Stained cells were
fixed in PBS containing 2% paraformaldehyde. Tetramer-based
enrichment was performed as described by Alanio et al.18
Briefly, 10–15  106 PBMCs were labeled for 30 minutes at
room temperature with the HLA-B*15:01/L-HDAg170–179
Figure 3. HLA-B*18–restricted CD8þ T-cell responses specific for L-HDAg46–54 drive viral escape and population-level evo-
lution of HDV. (A–E) Details as per the corresponding panels in Figure 1. In this case, the ancestral peptide is denoted as the
prototype, and the variant peptide is denoted as the consensus, reflecting a negative association between HLA-B*18 and
the viral polymorphism D47E. Representative data from patient 3 are shown in (D) and (E). M, mol/L; PMA, phorbol myristate
acetate.
















SMQGVPESPF tetramer coupled to phycoerythrin and enriched
using anti-PE beads with MACS technology (Miltenyi Biotec,
Germany). Frequencies of virus-specific CD8þ T cells were
calculated as described previously.18 Data were acquired using
an LSRFortessa flow cytometer and analyzed with FlowJo
software version 10 (FlowJo, Ashland, OR).
Results
Identification of HLA Class I–Associated Viral
Sequence Polymorphisms in L-HDAg
To assess the impact of HDV-specific CD8þ T-cell–
mediated selection pressure in vivo, we analyzed a cohort of
104 patients with chronic HDV/HBV infection for HLA class
I–associated viral sequence polymorphisms (HLA foot-
prints) in L-HDAg. Using a highly significant cutoff value
(P < .005) based on studies of other persistent viral in-
fections,19,20 we identified 21 viral sequence poly-
morphisms that were associated with specific HLA class I
alleles (Table 1).The strongest association linked residue 170 in L-HDAg
with HLA-B*15. All 8 HLA-B*15þ patients harbored viruses
with a serine (S) to asparagine (N) substitution at this
position (S170N) compared with only 16 of 96 HLA-B*15–
patients (P ¼ 2.9  10–8) (Figure 1A and C).
Only 5 of 21 significant polymorphisms (24%) were
associated with HLA-A alleles, whereas 16 of 21 significant
polymorphisms (76%) were associated with HLA-B alleles
(Table 1). Moreover, these HLA footprints were distributed
quite evenly across the central region of HDAg, sparing the
N-terminal 30 amino acids of S/L-HDAg, the C-terminal 25
amino acids of S-HDAg, and the entire C-terminal extension
unique to L-HDAg (Figure 2A).Validation of CD8þ T-Cell Epitopes and Viral
Escape Mutations in L-HDAg
To confirm the relevance of these associations, we used
in silico prediction tools to analyze viral amino acid
sequences for HLA class I binding motifs, guided by the
Figure 4. The rare allotype HLA-B*37 selects for viral escape in the CD8þ T-cell epitopes L-HDAg81–90 and L-HDAg100–108.
(A–E) Details as per the corresponding panels in Figure 1. (B) the BIMAS score (higher scores indicate higher binding affinities)
was used in place of the ANN 3.4 method, which does not include a prediction algorithm for HLA-B*37 binders. (D, E)
Representative data from patient 1 (epitope L-HDAg100–108). PMA, phorbol myristate acetate.




LIVER corresponding footprint data (see Materials and Methods).
In addition to 8mer, 9mer, and 10mer peptides, an
extended window incorporating 15 residues either side of
the HLA footprint was tested to allow the identification of
CD8þ T-cell epitopes associated with flanking mutations,
which can disrupt antigen processing and facilitate viral
escape.21–25 Using this approach with defined cutoffs (an
IC50  1000 nmol/L, a SYFPEITHI score  20, or a BIMAS
score  20), we identified 18 candidate CD8þ T-cell epi-
topes spanning 17 of the 21 HLA footprints (Figures 1B, 3B,
and 4B; Table 1; and Supplementary Table 3). As expected,
these candidates included 2 HLA-B*27-restricted epitopes
identified previously with the same sequence data set,
validating the overall strategy.6 Of note, 12 of 18 HLA
footprints were located within the respective candidate
epitopes, whereas 6 of 18 HLA footprints were located in
the regions flanking the respective candidate epitopes.
These latter footprints did not affect antigen processing in
silico, as predicted with an online algorithm (www.iedb.
org),26 but negative results were also obtained in similar
analyses of flanking mutations known to impair thegeneration of epitopes derived from HCV and HIV
(Supplementary Table 4).
We then evaluated the immunogenicity of candidate
epitopes in functional assays using peptide-stimulated CD8þ
T-cell lines generated from HLA class I–matched patients
with resolved HDV infection (n ¼ 12) or chronic HDV/HBV
infection (n ¼ 13) (Supplementary Table 2). Five novel
HDV-specific CD8þ T-cell epitopes were identified with this
approach (Table 1), including 1 restricted by HLA-B*15
(Figure 1), 1 restricted by HLA-B*18 (Figure 3), 2
restricted by HLA-B*37 (Figure 4), and 1 restricted by HLA-
B*41 (data not shown). In further experiments, we gener-
ated peptide-specific CD8þ T-cell lines targeting either the
prototype or variant epitopes and tested the impact of viral
sequence variation using IFN gamma production assays. As
shown in Figures 1D, 3D, and 4D, and more clearly in serial
dilution assays (Figures 1E, 3E, and 4E), the variant peptides
were recognized suboptimally by some, but not all,
prototype-specific CD8þ T cells. Conversely, variant-specific
CD8þ T cells responded poorly to the corresponding pro-
totype and variant peptides without exception, consistent
Figure 5. Viral escape in the HLA-B*15–restricted epitope L-HDAg170–179 after superinfection with HDV. (A) Clinical course of
HDV/HBV superinfection in patient 18 (HLA-A*24:02þ, -B*15:01þ, -B*35:02þ). (B) Viral sequences in patient 18 at early (week
0 and week 2) and late time points (week 71 and week 200) after superinfection with HDV. All longitudinal sequence variants
are shown (n ¼ 4). Dots indicate agreement with consensus across the study cohort. Residues with de novo mutations are
shown in red, and residues that revert to wild type are shown in green. The de novo mutation S170N is located in the confirmed
HLA-B*15–restricted epitope L-HDAg170–179 and corresponds to the linked footprint (Table 1). Also, the F27L reversion
colocalizes with an anchor residue for the pre-described HLA-A*02–restricted epitope L-HDAg26–34. ALT, alanine amino-
transferase; T, time.
















with population-level viral escape (Figures 1D and E, 3D and
E, 4D and E).
An association of special interest was detected at residue
47 (Figure 3A and C). Here, the consensus aspartate (D) was
conserved in 13 of 14 HLA-B*18þ patients, whereas the
variant glutamate (E) was found in 42 of 90 HLA-B*18–
patients (P ¼ .0027). This observation is compatible with
the notion that HLA-B*18 drives population-level evolution
from glutamate, which likely represents the ancestral res-
idue, to aspartate and further suggests that the E47D sub-
stitution does not markedly impair viral fitness, given the
relative paucity of sequence revertants in the absence of
HLA-B*18. In line with these interpretations, the variant
peptide (47E) induced a small but reproducible IFN gamma
response, whereas the consensus peptide (47D) was not
recognized in parallel assays (Figure 3D and E).
Viral Evolution During Superinfection With HDV
To probe the biological implications of these findings,
we characterized the emergence of viral escape mutations
in longitudinal samples from an HLA-B*15þ patient with
acute HDV/HBV superinfection (P18 in Supplementary
Table 2). This patient presented with alanineaminotransferase levels approaching 2000 U/L, which
declined to <500 U/L over a period of 1 week, and serum
HDV RNA levels approaching 107 IU/mL, which declined
by approximately 2 orders of magnitude in the first week
and subsequently relapsed to plateau at >107 IU/mL
(Figure 5A). Over a period of >200 weeks before initiation
of antiviral therapy with pegylated IFN alfa, viral sequence
analysis showed a total of 4 amino acid substitutions in
L-HDAg. Two of these mutations were reversions toward
the consensus sequence, and 2 mutations encoded de novo
substitutions away from the consensus sequence
(Figure 5B). One of the reversion mutations occurred at an
HLA-A*02 anchor residue, suggesting primary acquisition
of an escape virus from an HLA-A*02þ individual (patient
P18 lacked HLA-A*02). More importantly, 1 of the de novo
mutations (S170N) was a bone fide escape variant located
in L-HDAg170–179 SMQGVPESPF, matching the HLA-B*15
footprint identified in our cohort of patients with
chronic HDV/HBV infection (Figure 1 and Table 1). These
observations clearly show the longitudinal accumulation of
viral escape mutations in L-HDAg and tentatively link this
phenomenon with CD8þ T-cell failure in the context of
superinfection with HDV.





















HDV Sequence Polymorphisms Are Associated
With Infrequent HLA Class I Alleles
As noted, most of the HLA class I footprints identified in
our cohort were associated with HLA-B alleles (Table 1). In
further analyses, we realized that common HLA class I al-
leles, such as HLA-A*01, -A*02, -A*03, -B*07, -B*08, -B*35,
and -B*44, all of which occurred at frequencies >10% in the
German reference population, were not associated with viral
sequence polymorphisms (Figure 2B). Conversely, signifi-
cant footprints in the HDV genome were almost exclusively
associated with relatively uncommon HLA class I alleles,
namely HLA-A*29, -A*30, -B*13, -B*14, -B*15, -B*18, -B*27,
-B*37, -B*38, -B*41, -B*49, and -B*51 (Figure 2B and
Table 1).
To extend these observations, we compared HLA class
I allele frequencies in our cohort of patients with chronic
HDV/HBV infection with the corresponding HLA class I
allele frequencies in Germany, Italy, and Iran, where the
primary medical centers were located for recruitment
purposes (Figure 2B). Additional patients were recruited
from a medical center in Barcelona, but HLA class I allele
frequency data were not available for the general popu-
lation in Spain. The overall distribution of HLA class I
allele frequencies in our cohort of patients with chronic
HDV/HBV infection was similar to the overall distribution
of HLA class I allele frequencies in Germany, Italy, and
Iran (Figure 2B). However, the footprint-linked allele HLA-
B*51 was relatively common in our study cohort and in the
general populations of Italy and Iran (10%–11%), and we
were unable to identify an HLA-B*51–restricted candidate
epitope in HDV (Table 1 and Supplementary Table 3).
Other immune selection pressures, such as interactions
between the Bw4 motif and killer cell immunoglobulin-like
receptors, may therefore drive viral mutation in the
context of HLA-B*51. Similarly, the footprint-linked allele
HLA-B*18 was relatively common in our study cohort
(6.7%) and in the general population of Italy (9.7%). This
observation is compatible with the negative association
between HLA-B*18 and sequence variation at residue 47 in
L-HDAg.=
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accumulation of escape variants in vivo, whereas more
common HLA class I allotypes shape the circulating quasi-
species and therefore no longer select for de novo muta-
tions in HDV.HDV-Specific CD8þ T Cells Are Maintained at
Very Low Frequencies After Viral Escape
In line with previous studies,4,6 we were unable to detect
HDV-specific CD8þ T cells directly ex vivo, even with the aid
of fluorochrome-labeled tetramers corresponding to the
HLA-B*15-restricted epitope L-HDAg170–179 SMQGVPESPF
(Figure 6A, upper panels). We therefore characterized these
cells using a tetramer-based enrichment strategy.27,28
Distinct populations of tetramerþ CD8þ T cells were
detected after enrichment in all 7 HLA-B*15þ patients with
chronic HDV/HBV infection (patients 13, 14, 16, 17, 18, 21,
and 23) (Figure 6A, lower panels, and B). The frequencies of
these HLA-B*15–restricted HDV-specific CD8þ T cells were
low, however, subordinate even to rarely detectable virus-
specific CD8þ T cells in patients with chronic HCV infec-
tion (Figure 6B). In patients 13, 14, 17, 18, 21, and 23,
SMQGVPESPF-specific CD8þ T cells displayed a predomi-
nant effector-memory phenotype, whereas in patient 16,
SMQGVPESPF-specific CD8þ T cells displayed a predomi-
nant central-memory phenotype (Figure 6C). These HDV-
specific CD8þ T cells expressed intermediate to high levels
of PD-1 (Figure 6D), intermediate levels of the inhibitory
receptor KLRG1 (Figure 6D), and intermediate levels of the
transcription factors T-bet and Eomes (Figure 6E). In line
with these characteristics, which contrast with the typical
phenotype of terminally exhausted cells (PD-1hiKLRG1þT-
betdimEomeshi), SMQGVPESPF-specific CD8þ T cells also
expressed low levels of the activation marker CD38, akin to
HCV-specific CD8þ T cells targeting escape variants
(Figure 6F). Moreover, SMQGVPESPF-specific CD8þ T cells
preferentially displayed a PD-1þCD127þ phenotypec CD8þ T cells in patients with resolved or persistent HDV
Ag170–179 were tetramer-enriched from PBMCs isolated from
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LIVER(Figure 6G) and expressed relatively high levels of TCF1
(Figure 6H), a transcription factor that defines memory-like
cells with proliferative capacity.29 Similar levels of TCF1
were expressed by SMQGVPESPF-specific CD8þ T cells in a
patient (patient 5) with resolved HDV infection (Figure 6H).
Expression of the pro-survival factor BCL2 was more vari-
able, however, with the highest levels expressed by
SMQGVPESPF-specific CD8þ T cells in patient 5 (Figure 6H).
These phenotypic characteristics broadly mirror those
reported previously for HCV-specific CD8þ T cells in the
absence of antigenic stimulation, reflecting viral escape or
viral clearance.17,29 Although further studies are required to
establish such parallels across different viral infections, it is
notable that SMQGVPESPF-specific CD8þ T cells in patient
14, who retained a subpopulation of prototype viruses,
expressed relatively low levels of TCF1 and BCL2 in
conjunction with an atypical CD38þPD-1þCD127– pheno-
type (Figure 6F and G).Discussion
HDV/HBV infection is one of the few remaining difficult-
to-treat conditions in viral hepatitis, leading to liver
cirrhosis, liver failure, and hepatocellular carcinoma in
many patients.1,2 Despite the urgent need for novel pro-
phylactic and therapeutic interventions, remarkably little is
known about the natural repertoire of virus-specific CD8þ T
cells, which are thought to play a key role in immune pro-
tection against HDV. In this study, we analyzed HLA class
I–associated viral sequence polymorphisms in L-HDAg,
giving new insights into the immunobiology of HDV infec-
tion. First, we extended the repertoire of defined HDV-
specific CD8þ T-cell epitopes from 4, encompassing 2
restricted by HLA-A*024 and 2 restricted by HLA-B*27,6 to
9, now also encompassing 1 restricted by HLA-B*15, 1
restricted by HLA-B*18, 2 restricted by HLA-B*37, and
1 restricted by HLA-B*41. Second, we showed that viral
escape occurs during persistent HDV infection. Third, we
uncovered a link between viral escape and infrequent HLA
class I alleles, indicating population-level adaptation of HDV.
Finally, we showed that HDV-specific CD8þ T cells in pa-
tients with resolved or persistent HDV infection display
similar non–terminally exhausted phenotypes, consistent
with viral escape in the absence of clearance. In line with
this interpretation, HLA-B*15–restricted HDV-specific CD8þ
T cells that reproducibly select for viral escape could be
expanded from patients with chronic HDV/HBV infection,
whereas HDV-specific CD8þ T cells restricted by HLA class I
allotypes that less commonly select for viral escape could
not be expanded from patients with chronic HDV/HBV
infection.
The phenomenon of viral adaptation at the population
level may lead to a relative paucity of CD8þ T-cell epitopes
restricted by common HLA class I allotypes, which in turn
may impede the development of an effective vaccine against
HDV. In line with this prediction, viral sequence poly-
morphisms were not associated with the common HLA
alleles A*01, A*02, A*03, A*24, B*07, B*08, B*35, and B*44,
and suitable binding motifs for many of the correspondingallotypes were not present in the HDV proteome (L-HDAg).6
However, these findings need to be confirmed with direct
immunogenicity assays, because prediction algorithms are
potentially fallible, and certain epitopes may not be subject
to viral escape, particularly if they are located in biologically
constrained regions of L-HDAg. In this context, our experi-
mental strategy was not designed to identify CD8þ T-cell
epitopes that are not subject to viral escape. Moreover, our
study cohort did not include patients with acute HDV
infection, potentially limiting the detection of novel CD8þ T-
cell specificities. An unbiased approach will therefore be
required to define the full range of immunogenic epitopes
derived from HDV.30 The association between immunoge-
nicity and infrequent allotypes reported here may also
be confounded by HLA class I polymorphisms. For example,
the viral mutation S170N was found in all patients
with HLA-B*15:01 but was not found in patients
with HLA-B*15:10 or HLA-B*15:18 (data not shown).
Similarly, common polymorphisms in HLA-B*27 can lead to
subtype-specific patterns of epitope targeting in the context
of other persistent viral infections, including HCV and
HIV.31,32
Viral escape has direct implications for immune efficacy
and the development of immunotherapeutic strategies in
the setting of chronic HDV/HBV infection. Recent vaccine
studies in chimpanzees and humans with chronic HCV
infection showed good immunogenicity against non-
conserved viral epitopes, but the corresponding vaccine-
boosted CD8þ T cells were ineffective, because they failed
to recognize the circulating virus.33,34 Effective therapeutic
vaccines will therefore likely need to prime and/or boost
virus-specific CD8þ T cells that target conserved epitopes.
The most significant footprint-linked allele in the pre-
sent study was HLA-B*15, which has also been shown to
select for viral escape mutations during persistent HCV
infection.35 In addition, genetic association studies have
linked HLA-B*15 and/or its serological equivalent (B62)
with better outcomes after infection with HCV.36–38 How-
ever, it remains unclear if HLA-B*15 is associated with
spontaneous clearance of HDV, and, moreover, any such
associations will be extremely difficult to identify, given the
clinical heterogeneity of HDV-infected patients and the
requirement for co-infection with HBV. In our study cohort,
the presence of HDV-specific CD8þ T-cell responses did not
correlate with the outcome of infection (clearance vs
persistence). However, the presence of HDV amino acid
variations corresponding to polymorphisms associated with
the patient’s HLA alleles (Supplementary Table 1) displayed
a trend for association with both lower HDV RNA titers
(median, 20,638 IU/mL [range, 6 –20,098,000,000 IU/mL]
in patients with 1 variation vs median, 61,930 IU/mL
[range, 10–9,804,000 IU/mL] in patients without any vari-
ation; P ¼ .054 [Mann–Whitney test]) and lower alanine
aminotransferase levels (median, 73 U/L [range, 19–281 U/
L] in patients with 1 variation vs median 86 U/L [range,
31–507 U/L] in patients without any variation; P ¼ .070
[Mann–Whitney test]), respectively. These results suggest
that HLA class I footprint mutations indicate efficient CD8þ
T cell pressure, leading to partial control of viremia and
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ERliver inflammation. This interpretation is based on the
assumption, however, that partial cross-recognition of
escape variants occurs and is sufficient to exert pressure on
the virus.
It is particularly notable that our findings considerably
overlap with those reported previously in the setting of
persistent infection with HCV or HIV. For example, in all 3
infections, virus-specific CD8þ T-cell pressure can select
escape variants to fixation (HDV: HLA-B*15–associated
polymorphism S170N; HCV: HLA-A*01–associated poly-
morphism Y1444F)39 and drive viral evolution at the pop-
ulation level to extinguish commonly restricted epitopes




40 Similarly, in all 3 in-
fections, virus-specific CD8þ T cells are preferentially
restricted by HLA-B,41–44 rare allotypes confer a particular
advantage,45 and viral escape mutations undergo reversion
in the absence of selection pressure after transmission.46,47
Finally, in all 3 infections, CD8þ T cells targeting escape
variants display a memory-like phenotype, indicating a loss
of antigenic drive.17,25,29
Despite these striking parallels across distinct viruses
with respect to adaptive host–pathogen interactions, the
immunobiology of HDV infection is complicated by the
mandatory requirement for co-infection with HBV. Much
work will therefore be required to unravel the parameters
that govern clinical outcome in the midst of constantly
shifting immune responses that simultaneously target
rapidly evolving antigens derived from 2 different viruses in
a genetically diverse host population. The findings reported
here are nonetheless informative with respect to the un-
derlying cellular and molecular processes and can be
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